This paper summarizes the implications of recent TAVR program expansion, supports the 2019 multisociety expert consensus recommendation of Level 1 and Level 2 valve centers, and defines the important ...
Medtronic will invest $90M in Anteris Technologies for DurAVR TAVR device development, contingent on a $200M IPO.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results